Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024 07:00 ET
|
Neumora Therapeutics, Inc.
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of...
Neumora Therapeutics to Participate in Upcoming Conferences in May
May 06, 2024 07:00 ET
|
Neumora Therapeutics, Inc.
WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and...
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
April 15, 2024 06:30 ET
|
Neumora Therapeutics, Inc.
WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical...
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
March 13, 2024 07:00 ET
|
Neumora Therapeutics, Inc.
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024 07:00 ET
|
Neumora Therapeutics, Inc.
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong...
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
January 22, 2024 07:00 ET
|
Neumora Therapeutics, Inc.
WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 07:00 ET
|
Neumora Therapeutics, Inc.
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
December 12, 2023 07:00 ET
|
Neumora Therapeutics, Inc.
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
November 27, 2023 07:00 ET
|
Neumora Therapeutics, Inc.
WATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the...
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 01, 2023 07:00 ET
|
Neumora Therapeutics, Inc.
Navacaprant Phase 3 KOASTAL program in major depressive disorder on track; planned initiation of Phase 2 bipolar depression trial in 1H24 Progressing NMRA-511 and NMRA-266 toward near-term clinical...